Comparison of RECIST 1.1, mRECIST and PERCIST for assessment of peptide receptor radionuclide therapy treatment response in metastatic neuroendocrine tumors

IF 1.5 Q3 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

Current Problems in Diagnostic Radiology Pub Date : 2024-10-04 DOI:10.1067/j.cpradiol.2024.10.003

Jack Zhao , Kaustav Bera , Amr Mohamed , Qiubai Li , Nikhil Ramaiya , Sree Harsha Tirumani

{"title":"Comparison of RECIST 1.1, mRECIST and PERCIST for assessment of peptide receptor radionuclide therapy treatment response in metastatic neuroendocrine tumors","authors":"Jack Zhao , Kaustav Bera , Amr Mohamed , Qiubai Li , Nikhil Ramaiya , Sree Harsha Tirumani","doi":"10.1067/j.cpradiol.2024.10.003","DOIUrl":null,"url":null,"abstract":"<div><h3>Purpose</h3><div>To compare RECIST 1.1, modified RECIST (mRECIST) and PERCIST for assessment of Peptide Receptor Radionuclide Therapy <strong>(</strong>PRRT) treatment response in metastatic neuroendocrine tumors.</div></div><div><h3>Materials</h3><div>In this IRB-approved, HIPAA compliant retrospective study, patients treated with PRRT between July 2019 and Dec 2022 were identified. Inclusion criteria were presence of at least one pre-and one post-treatment imaging (CT, MRI, Ga 68 or Cu64 DOTATATE PET/CT) within one year of the start and end of PRRT respectively. The imaging was reviewed independently by two radiologists using RECIST 1.1, modified RECIST (mRECIST) and PERCIST criteria. Response of first post treatment scan and presence of disease progression during follow-up were recorded along with the date of best response and disease progression. Statistical analysis was performed to determine inter-reader agreement and agreement between the various response criteria using kappa statistics.</div></div><div><h3>Results</h3><div>Best response by RECIST 1.1 was recorded in 26 patients (PR-7, SD- 13, PD- 6), by mRECIST in 22 patients (PR-7, SD- 10, PD- 5), by PERCIST in 14 patients (PR-4, SD- 3, PD- 7). Inter-reader agreement was highest for PERCIST (weighted kappa 0.921, standard error 0.078 95% CI 0.769 to 1.000) followed by RECIST 1.1 (weighted kappa 0.897, standard error 0.071 95% CI 0.758 to 1.000) and mRECIST (weighted kappa 0.883, standard error 0.079 95% CI 0.727 to 1.000).</div></div>","PeriodicalId":51617,"journal":{"name":"Current Problems in Diagnostic Radiology","volume":"54 2","pages":"Pages 228-232"},"PeriodicalIF":1.5000,"publicationDate":"2024-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Problems in Diagnostic Radiology","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0363018824001786","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose

To compare RECIST 1.1, modified RECIST (mRECIST) and PERCIST for assessment of Peptide Receptor Radionuclide Therapy (PRRT) treatment response in metastatic neuroendocrine tumors.

Materials

In this IRB-approved, HIPAA compliant retrospective study, patients treated with PRRT between July 2019 and Dec 2022 were identified. Inclusion criteria were presence of at least one pre-and one post-treatment imaging (CT, MRI, Ga 68 or Cu64 DOTATATE PET/CT) within one year of the start and end of PRRT respectively. The imaging was reviewed independently by two radiologists using RECIST 1.1, modified RECIST (mRECIST) and PERCIST criteria. Response of first post treatment scan and presence of disease progression during follow-up were recorded along with the date of best response and disease progression. Statistical analysis was performed to determine inter-reader agreement and agreement between the various response criteria using kappa statistics.

Results

Best response by RECIST 1.1 was recorded in 26 patients (PR-7, SD- 13, PD- 6), by mRECIST in 22 patients (PR-7, SD- 10, PD- 5), by PERCIST in 14 patients (PR-4, SD- 3, PD- 7). Inter-reader agreement was highest for PERCIST (weighted kappa 0.921, standard error 0.078 95% CI 0.769 to 1.000) followed by RECIST 1.1 (weighted kappa 0.897, standard error 0.071 95% CI 0.758 to 1.000) and mRECIST (weighted kappa 0.883, standard error 0.079 95% CI 0.727 to 1.000).

查看原文本刊更多论文

比较 RECIST 1.1、mRECIST 和 PERCIST 用于评估转移性神经内分泌肿瘤的肽受体放射性核素治疗反应。

目的：比较 RECIST 1.1、改良 RECIST（mRECIST）和 PERCIST 对转移性神经内分泌肿瘤的肽受体放射性核素疗法（PRRT）治疗反应的评估：在这项经 IRB 批准、符合 HIPAA 标准的回顾性研究中，确定了 2019 年 7 月至 2022 年 12 月期间接受 PRRT 治疗的患者。纳入标准是在 PRRT 开始和结束后一年内，分别至少有一次治疗前和一次治疗后影像学检查（CT、MRI、Ga 68 或 Cu64 DOTATATE PET/CT）。影像学检查由两名放射科医生根据 RECIST 1.1、改良 RECIST (mRECIST) 和 PERCIST 标准独立完成。记录治疗后首次扫描的反应和随访期间的疾病进展情况，以及最佳反应和疾病进展的日期。采用卡帕统计法进行了统计分析，以确定阅读者之间的一致性以及各种反应标准之间的一致性：结果：26 名患者（PR-7，SD- 13，PD- 6）记录了 RECIST 1.1 最佳反应，22 名患者（PR-7，SD- 10，PD- 5）记录了 mRECIST 最佳反应，14 名患者（PR-4，SD- 3，PD- 7）记录了 PERCIST 最佳反应。PERCIST（加权卡帕0.921，标准误差0.078，95% CI 0.769-1.000）的读数间一致性最高，其次是RECIST 1.1（加权卡帕0.897，标准误差0.071，95% CI 0.758-1.000）和mRECIST（加权卡帕0.883，标准误差0.079，95% CI 0.727-1.000）。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Problems in Diagnostic Radiology RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING-

CiteScore

3.00

自引率

0.00%

发文量

113

审稿时长

46 days

期刊介绍： Current Problems in Diagnostic Radiology covers important and controversial topics in radiology. Each issue presents important viewpoints from leading radiologists. High-quality reproductions of radiographs, CT scans, MR images, and sonograms clearly depict what is being described in each article. Also included are valuable updates relevant to other areas of practice, such as medical-legal issues or archiving systems. With new multi-topic format and image-intensive style, Current Problems in Diagnostic Radiology offers an outstanding, time-saving investigation into current topics most relevant to radiologists.